p53 Wildtype Cancer Research Results

p53 Wildtype, p53 Wildtype: Click to Expand ⟱
Source: HalifaxProj(upregulate)
Type:
The term "wildtype" refers to the normal, non-mutated form of the p53 protein. In this state, p53 is functional and can effectively carry out its tumor-suppressing activities.
Wildtype p53 can induce cell cycle arrest, promote DNA repair, initiate apoptosis (programmed cell death), and regulate other genes involved in these processes. It responds to various stress signals, such as DNA damage, hypoxia, and oncogene activation.

In Cancers with Wild-Type p53:
Intact p53 function is associated with better control of cell growth and an improved response to DNA damage.
Retention of wild-type p53 generally indicates a more favorable prognosis.

Wild-Type p53:
Classic tumor-suppressing role (i.e., anti-tumorigenic). It prevents the proliferation of cells with damaged DNA.
Mutant p53:
Can be considered protumorigenic due to loss of normal function and, in certain cases, due to “gain-of-function” activities.
Scientific Papers found: Click to Expand⟱
6527- CRV,    Preventive effect of D-carvone during DMBA induced mouse skin tumorigenesis by modulating xenobiotic metabolism and induction of apoptotic events
- in-vivo, Melanoma, NA
AntiTum↑, D-carvone at 20 mg dose significantly prevents skin carcinogenesis
P450↓, decreased levels of phase I enzymes (Cyt P450 and-Cyt b5) with increased levels of phase II enzymes (GR, GST and GSH) and increased expression of Bax, caspase-3 and caspase-9
GSR↑,
GSTs↑,
GSH↑,
BAX↑,
Casp3↑,
Casp9↑,
Bcl-2↓, decreased expression of mutated p53 and Bcl-2 in animals treated with DMBA and D-carvone at 20 mg dose.
p53 Wildtype↓,
chemoPv↑, D-carvone can be used as a chemopreventive agent against skin cancer
Apoptosis↑, as it induces apoptosis in cancer

6671- Deg,    A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy
- in-vitro, Nor, BEAS-2B - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HSP90↓, natural compound deguelin has promising preventive and therapeutic activity against diverse cancers by directly binding to heat-shock protein 90 (Hsp90) and thus suppressing its function.
toxicity↝, Potential side effects of deguelin over a certain dose, however, could be a substantial obstacle to its clinical use.
eff↑, One derivative, SH-14, showed several features of potential superiority for clinical use:
chemoPv↑, novel derivative SH-14 has strong potential for cancer chemoprevention and therapy, with equivalent efficacy and lesser toxicity (versus deguelin).
p53 Wildtype↓, hich leads to decreased expression of a number of Hsp90 client proteins, including mutated p53, cyclin-dependent kinase 4, mitogen-activated protein kinase (MAPK) kinase-1/2 (MEK1/2), Akt and hypoxia-inducible factor (HIF)-1α,
CDK4↓,
MAPK↓,
Hif1a↓,
selectivity↑, Deguelin has antitumor activity in vitro or in vivo at doses producing no toxic effects to normal cells or tissues and so may be a promising cancer preventive and therapeutic agent
compI↓, Researchers originally identified deguelin as a potent mitochondria complex I, NADH dehydrogenase inhibitor and implicated mitochondrial dysfunction and diminished complex I activity as factors in the pathophysiology of Parkinson’s disease (PD;
TumCP↓, Synthesis of five derivatives of deguelin that inhibit Hsp90 function and lung cancer cell proliferation
BioAv↑, SH-14 has better aqueous solubility than deguelin


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

compI↓, 1,   GSH↑, 1,   GSR↑, 1,   GSTs↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   MAPK↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

p53 Wildtype↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   eff↑, 1,   P450↓, 1,   selectivity↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoPv↑, 2,   toxicity↝, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: p53 Wildtype, p53 Wildtype
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:237  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page